61.6 F
San Diego
Thursday, Jun 13, 2024
-Advertisement-

Seragon Announces Closing of Its Acquisition By Genentech

San Diego-based Seragon Pharmaceuticals Inc. today announced the closing of its acquisition by Genentech Inc., a member of the Roche Group.

Deal terms included $725 million in cash up front along with $1 billion in contingent development milestone payments for total transaction value up to $1.73 billion.

The acquisition includes Seragon’s entire selective estrogen receptor degrader program, including its most advanced compound which is currently being evaluated in postmenopausal women with locally advanced estrogen receptor positive breast cancer.

-Advertisement-

Featured Articles

Hair Today, Hair Tomorrow

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-